Journal: Scientific Reports

Article Title: Suppressive effects of Momordica charantia MAP30 on the senescence, proliferation and migration of bladder cancer cells mediated by CENPA

doi: 10.1038/s41598-025-14977-y

Figure Lengend Snippet: MAP30 treatment inhibits bladder cancer cell migration. ( A , B ) Representative images of the results of wound healing assay and the quantitative results in 5637 cells treated with MAP30. ( C , D ) Representative images of the results of wound healing assay and the quantitative results in T24 cells treated with MAP30. ( E , F ) Representative images of the results of the transwell migration assay and the quantitative results. ( G ) Representative images of western blotting results of CDH1 and CDH2, and ( H ) the quantitative results. CDH1, E-cadherin. CDH2, N-cadherin.

Article Snippet: The sections were processed for IHC by incubating with specific primary antibodies, including CDH1 (1:100 dilution, ProteinTech Group, Inc., USA), CDH2 (1:100 dilution, ProteinTech Group, Inc., USA) and ki67 (1:100 dilution, ProteinTech Group, Inc., USA).

Techniques: Migration, Wound Healing Assay, Transwell Migration Assay, Western Blot

Journal: Scientific Reports

Article Title: Suppressive effects of Momordica charantia MAP30 on the senescence, proliferation and migration of bladder cancer cells mediated by CENPA

doi: 10.1038/s41598-025-14977-y

Figure Lengend Snippet: MAP30 inhibits tumorigenesis in vitro and in vivo. ( A , B ) Representative images of the results of soft agar clone formation assay and the quantitative results in 5637 and T24 cells treated with MAP30. ( C ) Images of subcutaneous tumors formed in nude mice subcutaneously injected with T24 cells and treated with different concentrations of MAP30. Statistical results of changes in ( D ) volume and ( E ) weight of subcutaneous tumors isolated from nude mice ( n = 8). ( F ) Representative images of the results of HE and IHC staining of tumor sections. ( G ) Statistic results of the average optical density for CDH1 and CDH2. ( H ) Statistic results of the percent of Ki67 positive cells. CDH1, E-cadherin. CDH2, N-cadherin.

Article Snippet: The sections were processed for IHC by incubating with specific primary antibodies, including CDH1 (1:100 dilution, ProteinTech Group, Inc., USA), CDH2 (1:100 dilution, ProteinTech Group, Inc., USA) and ki67 (1:100 dilution, ProteinTech Group, Inc., USA).

Techniques: In Vitro, In Vivo, Tube Formation Assay, Injection, Isolation, Immunohistochemistry

Journal: Scientific Reports

Article Title: Suppressive effects of Momordica charantia MAP30 on the senescence, proliferation and migration of bladder cancer cells mediated by CENPA

doi: 10.1038/s41598-025-14977-y

Figure Lengend Snippet: CENPA overexpression reverses the anti-tumor effects of MAP30. ( A , B ) Representative images of the results of the EdU assay and the quantitative results. ( C , D ) Representative images of the results of the transwell migration assay and the quantitative results. ( E , F ) Representative images of the results of β-Gal immunofluorescence assay and the quantitative results. ( G ) Representative images of western blotting results of CDH1, CDH2 and p21, and ( H , I ) the quantitative results. β- Gal, β-Galactosidase. CDH1, E-cadherin. CDH2, N-cadherin.

Article Snippet: The sections were processed for IHC by incubating with specific primary antibodies, including CDH1 (1:100 dilution, ProteinTech Group, Inc., USA), CDH2 (1:100 dilution, ProteinTech Group, Inc., USA) and ki67 (1:100 dilution, ProteinTech Group, Inc., USA).

Techniques: Over Expression, EdU Assay, Transwell Migration Assay, Immunofluorescence, Western Blot